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Background/Aims: To investigate epidemiologic characteristics, clinical and eco-
nomic burdens, and factors associated with mortality in complicated skin and 
skin structure infection (cSSSI) patients in Korea.
Methods: A retrospective, observational, nationwide study was conducted between 
April to July 2012 at 14 tertiary-hospitals in Korea. Eligible patients were hospital-
ized adults with community acquired cSSSI, who underwent surgical intervention 
and completed treatment between November 2009 and October 2011. Data on 
demography, clinical characteristics, outcomes and medical resource utilization 
were collected through medical record review. Direct medical costs were calculat-
ed by multiplying quantities of resources utilized by each unit price in Korea.
Results: Of 473 patients enrolled, 449 patients (except 24 patients with no record 
on surgical intervention) were eligible for analysis. Microbiological testing was 
performed on 66.1% of patients and 8.2% had multiple pathogens. Among culture 
confirmed pathogens (n = 297 patients, 340 episodes), 76.2% were gram-positive 
(Staphylococcus aureus; 41.2%) and 23.8% were gram-negative. The median duration 
of hospital stay was 16 days. Among treated patients, 3.3% experienced recurrence 
and 4.2% died in-hospital. The mean direct medical costs amounted to $4,195/
person, with the greatest expenses for hospitalization and antibiotics. The in-hos-
pital mortality and total medical costs were higher in combined antibiotics ther-
apy than monotherapy (p < 0.05). Charlson’s comorbidity index ≥ 3, standardized 
early warning scoring ≥ 4, sub-fascia infections and combined initial therapy, 
were all found to be associated with higher mortality.
Conclusions: Korean patients with community-onset cSSSI suffer from consider-
able clinical and economic burden. Efforts should be made to reduce this burden 
through appropriate initial treatment.
Keywords: Complicated skin and skin structure infection; Economic; Clinical bur-
den; Initial antibiotics
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INTRODUCTION
Skin and skin structure infection (SSSI) is an infection of 
the skin and associated tissues, and thus, the equivalent 
term of skin and soft tissue infections is identically used. 
According to United States data, hospital admissions for 
adult patients due to SSSI are increasing [1]. The term 
‘complicated’ SSSI (cSSSI) is often used when the infec-
tion requires surgical intervention and/or the infectious 
process involves (suspected or confirmed) deeper soft 
tissue; however, there is no universally accepted criteria 
for defining cSSSIs [2-4]. Complicated SSSIs usually in-
clude secondary infections of diseased, acute wound in-
fections (traumatic, bite-related), surgical site infections 
(deep, organ-space), chronic wound infections (diabetic 
foot, venous stasis ulcers, pressure sores) and perianal 
cellulitis [5]. 
The etiology of CSSSIs is usually polymicrobial in na-
ture. Most commonly implicated pathogens are gram 
positive cocci, and particularly Staphylococcus aureus. 
Gram negative bacilli and anaerobic bacteria can be 
encountered in more complicated cases of cSSSI [4-6]. 
These etiological differences among CSSSIs can depend 
on the type of infection, as well as if the infection is 
community-acquired or nosocomial [7]. 
Complicated SSSIs have a high disease burden and 
are sometimes difficult to diagnose. Hence, cSSSIs may 
progress to severe necrotizing fasciitis entailing subcuta-
neous connective tissues and stretch deep into other soft 
tissues [8,9]. These infections may be inexorably progres-
sive despite treatment even when limb-or life-threaten-
ing [5]. An estimated 3% of cSSSI patients face death and 
the mortality rate increases sharply to 29% when it pro-
gresses to necrotizing fasciitis [9,10]. The high economic 
burden of treatment further exacerbates the problem; 
treatment costs are estimated to be as high as United 
States dollar (USD) 48,033 per person, which increases if 
the patient has additional procedures, ICU admission, or 
any other treatments [11]. It follows that prompt diagno-
sis and initiation of effective antibiotic therapy is crucial 
in the management of cSSSI patients.
Only a few studies have assessed the burden of cSSSI 
infections and factors incurring additional burden on 
patients with cSSSI in Korea. This study was conducted 
to provide the following information regarding com-
munity-onset cSSSIs in Korea: (1) epidemiologic in-
formation, (2) clinical outcomes of treatment, (3) direct 
medical cost associated with treatment, and (4) factors 
associated with mortality in cSSSI. 
METHODS
This retrospective, observational, nationwide study was 
conducted at 14 tertiary hospitals in Korea between April 
2012 and July 2012. The study was approved by the Insti-
tutional Review Boards (IRBs) of all participating hos-
pitals. All procedures have, therefore, been performed 
in accordance with the ethical standards of the institu-
tional and/or national research committees and with the 
1964 Declaration of Helsinki and its later amendments 
or comparable ethics standards. The IRB approval 
number of the Gachon University College of Medicine, 
which is responsible for this study, is GIRBA-2655-2012. 
Written informed consents was waived a retrospective 
nature of our study by the board. The IRB numbers 
for the other participating hospitals are as follows: 
KUGH11243-001, 2011-280, 2011-12-123, 4-2011-0735; ECT 
12-02A-29, 3-2011-0276; PCR-11-202, 11-317 12.16; KNUH 
2011-12-019, 11-91, 11-199, 11-186, 2012-01-006.
Patients
Patients were considered eligible for enrollment if they 
met all of the following criteria: (1) aged ≥ 18 years; (2) 
required surgical interventions and were admitted to 
hospitals with the diagnosis of community-onset cSSSI 
according to the following international classification of 
disease (ICD)-10 codes; major abscess (L02.0 to L02.9), 
necrotizing cellulitis (L03.0 to L03.9), cellulitis merged 
with deep myositis (M60.0, M60.8, M60.9), pyomyositis 
(M60.0, M60.8, M60.9), necrotizing fasciitis (M72.6) and 
traumatic infection (T79.3); (3) culture-confirmed infec-
tion within 48 hours of hospitalization or underwent 
treatment for culture-confirmed infection from the sur-
gical specimen. 
Patients who met at least one of following criteria 
were excluded: (1) experienced an uncomplicated skin 
and skin structure infection; (2) had hospital acquired 
cSSSI; (3) recovered after treatment of more than 2 days 
in another hospital; (4) transferred to another hospital 
during treatment or was discharged against medical ad-
vice; (5) presented with osteomyelitis close to the infect-
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ed area or deep site tissue infection other than skin and 
skin structure infection (e.g., deep neck infection, psoas 
abscess); (6) received plasmapheresis or hemoperfusion; 
(7) had concurrent infection of non-removable prosthet-
ic materials (e.g., permanent cardiac pacemaker battery 
packs or joint replacement prostheses); (8) suffered from 
neutropenia (absolute neutrophil count < 500 cells/mm3) 
or human immunodeficiency virus of CD4 count < 100 
cells/mm3 within the most recent 6 months; (9) received 
more than two immunosuppressants or received pred-
nisolone dosage of 40 mg daily (or equivalent) for more 
than once a week within the most recent 3 months; (10) 
received chemotherapy or radiotherapy within the most 
recent 3 months; (11) was participating in some other 
clinical research; or (12) was deemed unsuitable for the 
study as judged by the researcher (e.g., tuberculosis or 
nontuberculous mycobacterial infection, fungal infec-
tion, Vibrio vulnificus sepsis patient, etc.). 
The 473 patients with cSSSI who completed treatment 
between November 2009 and October 2011 were en-
rolled and the number of enrolled patients in each hos-
pital was restricted to a maximum of 40 patients. Of the 
473 patients, 24 patients who did not record the surgical 
intervention in their case report form were excluded. 
The remaining 449 patients who met the inclusion cri-
teria were analyzed in our study. Most patients’ medical 
charts were reviewed for cSSSI treatment throughout 
their first and last hospital visits.
Data collection & quantification of medical resource 
utilization
The following data were collected through the medical 
chart review: (1) demography data including age and gen-
der; (2) clinical characteristics including disease severity 
(standardized early warning scoring [SEWS]), comorbid-
ities (Charlson’s comorbidity index, CCI), and data on 
infections and its treatment; (3) clinical outcomes data 
including length of hospital stay, admission to intensive 
care unit (ICU), recurrence within 3 months of the treat-
ment completion and in-hospital mortality (defined as 
death related and/or non-related with cSSSI). 
All medical resource utilizations during the entire 
cSSSI treatment period were collected by retrospective 
review of patient medical records. The cSSSI treatment 
period was defined as the period between the first and 
last hospital visit. The direct medical costs were calcu-
lated by multiplying quantities of resources utilized by 
the unit price of each resource. The unit price of each 
resource was obtained from the Health Insurance Price 
List (Korea HIRA 2010), and the medication cost was 
from the weighted average cost (2010). Categories of 
costs included hospitalization (outpatient visit, emer-
gency department visit, intensive care unit admission 
and general department admission), antibiotics, other 
medications (other than antibiotics), laboratory tests 
(blood and urine tests), imaging tests (X-ray, computed 
tomography, magnetic resonance imaging, sonogra-
phy, etc.), diagnostic tests (culture, gram stain through 
blood culture, wound or drainage, etc. for etiological di-
agnosis), and surgeries and procedures (e.g., incision & 
drainage, etc.). All costs were presented in USD ($) using 
the exchange rate of 1,100 KRW = $1; this exchange rate 
approximately corresponds to the value of the average 
exchange rate of USD during the past 10 years. 
Statistical analysis 
Descriptive analysis was performed to assess demograph-
ic and clinical characteristics, distribution of pathogens, 
and clinical and economic burden of disease. Contin-
uous variables were shown as the mean with standard 
deviation (SD), or median with interquartile range (IQR). 
Median with IQR was used to represent values when the 
data were not following a normal distribution. The cost 
was log-transformed since it did not follow a normal 
distribution. Frequency and proportions were calculat-
ed for categorical variables. Chi-square test was used to 
evaluate differences in CCI, SEWS, depth of infection 
and clinical burden (except hospital length of stay) be-
tween initial therapy types (monotherapy and combined 
therapy). Hospital length of stay between initial therapy 
types was compared with the Mann-Whitney test. 
Logistic regression was performed to identify risk 
factors that were associated with the mortality of com-
munity-onset cSSSI patients. The candidate variables, 
which were anticipated to be associated with mortality, 
were selected based on the literature and clinical expe-
riences, and included in the model. Then, the variables 
were selected by the backward elimination method. 
A two-sided p value of 0.05 was considered statistically 
significant. All statistical analyses were performed using 
SPSS statistical program version 20.0 (IBM Co., Armonk, 
NY, USA).
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Patient characteristics are presented in Table 1. Of the 
449 patients (mean age, 54 .6; 64.6% male) who were ad-
mitted with a community-onset cSSSI, 415 (92.5%) were 
≤ 3 in SEWS at the time of admission and 247 (55.0%) 
had no comorbidities. The leading type of infection was 
major abscess (n = 233, 51.9%), followed by necrotizing 
cellulitis (n = 144, 31.1%). More than two infectious diag-
noses were made in 61 (13.6%) patients. The infections 
spread into subcutaneous tissues in 192 (42.8%) patients, 
reached below fascia in 173 (38.5%) patients and were 
most commonly found in the lower extremities (n = 211, 
44.1%). More than half of the cSSSI patients were admit-
ted via the emergency room (ER) (n = 240, 53.5%). 
Clinical and economic burden 
The median duration of hospital stay for cSSSI treat-
ment was 16 days (IQR, 8 to 28). Admission to the inten-
sive care unit (ICU) was necessary for 44 (9.8%) patients. 
Recurrence of disease within 3 months was observed in 
15 (3.3%) patients and 19 (4.2%) cases of in-hospital mor-
tality were recorded (Table 1). 
Table 1. Characteristics of study patients and clinical bur-
den of community-onset complicated skin and skin struc-
ture infections (n = 449) 
Characteristic Value
Age, yr 54.6 ± 16.8
Male sex 290 (64.6)









≥ 5 18 (4.0)
Infections
Type of infectiona
Major abscess 233 (51.9)
Necrotizing cellulitis 144 (31.1)
Cellulitis with deep myositis 31 (6.9)
Pyomyositis 31 (6.9)
Necrotizing fasciitis 62 (13.8)
Traumatic infection 12 (2.7)







Lower extremities 211 (44.1)
Buttock 80 (16.7)
Head and neck 73 (15.3)
Upper extremities 74 (15.5)
Trunk 40 (8.4)
Admission via ER 240 (53.5)
Clinical burden
Hospital length of stay, day 16 (8–28)
ICU admission 44 (9.8)
Recurrence after 3 months 15 (3.3)  
In-hospital mortality 19 (4.2)
Values are presented as mean ± SD or number (%).
ER, emergency room; ICU, intensive care unit.
aMultiple answers.
bThe patients who had comorbid infection of more than 
  2 type of infection.
























Surgery & Procedures cost
Imaging cost
Total costs
    Mean (KRW) ± SD
1,463,372 ± 1,338,877
   726,373 ± 1,034,791
   453,151 ± 1,674,181
   128,948 ± 190,384
   638,244 ± 946,410
   725,708 ± 1,957,186
   479,410 ± 539,396
4,614,997 ± 6,514,812
Mean (USD) ± SD
1,330 ± 1,217
   660 ± 941
   412 ± 1,522
   117 ± 173
   580 ± 860
   660 ± 1,779
   436 ± 490
4,195 ± 5,923
Figure 1. Economic burden of community-onset complicat-
ed skin and skin structure infections. KRW, Korean won; 
USD, United States dollar.
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For cSSSI treatment, the mean total direct medical 
cost was $4,195 ± 5,923 per person. Hospitalization costs 
accounted for the maximum total direct medical cost, 
followed by the cost of antibiotics ($1,330 ± 1,217 and 
$660 ± 941, respectively). Costs for surgical procedures 
and imaging tests were also high with a mean of $660 ± 
1,779 and $436 ± 490, respectively (Fig. 1).
Distribution of pathogens 
This study analyzed the tests of 449 patients whose spec-
imens were obtained within 2 days after admission. As 
shown in Table 2, 297 (66.1%) of 449 patients were iden-
tified by the microbiology test. Multiple pathogens were 
found in 37 (8.2%) patients; 13 (2.9%) had ≥ 2 gram-posi-
tive pathogens, four (0.9%) had ≥ 2 gram-negative patho-
gens, and 20 (4.5%) patients had both gram-positive and 
gram-negative pathogens (mixed pathogens). Superin-
fection was observed in 69 patients, and among those 
with superinfection 19 patients underwent two times of 
changes. Most specimens were taken from tissue, drain-
age or an aspirated wound, and other specimens were 
taken from abscesses and pustules, while only 26 (8.6%) 
used blood cultures. Among culture confirmed patho-
gens (episode = 340) which did not include coagulase 
negative Staphylococcus, Corynebacterium, Micrococcus spp., 
Bacillus spp. and gram-positive rods (episode = 9), most 
of the infections were caused by gram-positive bacteria 
(episode = 259, 76.2%) which were mainly S. aureus (epi-
sode = 140, 41.2%) and group B Streptococcus (episode = 31, 
9.1%). There were 81 (23.8%) episodes of gram-negative 
bacterial infections. 
Comparison by initial therapy
Initial therapy consisted of monotherapy and combined 
therapy. Monotherapy and combination therapy were 
determined according to the number of antibiotics in 
Variable No. (%)
No growth 152 (33.9)





≥ 2 Gram-positive pathogen 
 (no gram-negative pathogens)
13 (2.9)
≥ 2 Gram-negative pathogen 
 (no gram-positive pathogens)
4 (0.9)










Microbiology results: culture-confirmed  
 pathogens (episode case = 340)b
Gram positive 259 (76.2)
Staphylococcus aureus 140 (41.2)
Group B Streptococcus 31 (9.1)
Variable No. (%)
Group A Streptococcus 21 (6.2)
Enterococcus faecalis 4 (1.2)
Others 63 (18.5)
Gram negative 81 (23.8)
Escherichia colic 19 (5.6)
Bacteroides fragilis 3 (0.9)
Klebsiella species 3 (0.9)
Proteus mirabilis 10 (2.9)
Pseudomonas aeruginosa 9 (2.6)
Enterobacter species 8 (2.4)
Acinetobacter species 6 (1.8)
Citrobacter species 5 (1.5)
Others 18 (5.3)
aDefined as the first positive specimen during the episode. 
Not counted if no specimen were positive. “Other” specimens 
included tissue, wound drainage or aspirate, and other mis-
cellaneous specimens taken from abscesses, pustules, etc.
bDenominator for percent is the number of episodes with 
any positive pathogen (episode case = 340). Pathogen results 
were not mutually-exclusive. The following organisms were 
considered contaminants and not included: coagulase nega-
tive Staphylococcus, Corynebacterium, Micrococcus spp., Bacillus 
spp., gram positive rods (episode case = 9). 
cExtended spectrum β-lactamase producing bacteria was de-
tected from Escherichia coli (1 case).
Table 2. Distributions of pathogens of community-onset complicated skin and skin structure infections (n = 449)
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treatment. Regardless of the class counted in antibiot-
ics, using only one antibiotic drug was defined as mono-
therapy whereas using multiple antibiotics was consid-
ered combination therapy. The proportion of CCI ≥ 3 in 
monotherapy and combined therapy were similar (11.4% 
vs. 13.0%). The proportion of SEWS ≥ 4 and deep fas-
cial space infections also were not significantly different 
(SEWS ≥ 4: 5.9% vs. 8.9%; and deep fascial space infec-
tions: 35.1% vs. 41.3%, respectively). The median length 
of hospital stay for cSSSI treatment with combined ther-
apy (19 days) was longer than but not significantly differ-
ent from monotherapy (14 days). Admissions to the ICU 
in patients treated with monotherapy (6.9%) were low-
er than combined therapy (12.1%), but a higher disease 
recurrence within 3 months was observed in patients 
treated with monotherapy (5.1%) than combined thera-
py (2.2%). However, these differences were not signifi-
cant. The proportion of in-hospital mortality in patients 
treated with combined therapy (6.1%) was significantly 
higher than monotherapy (2.0%). 
The total direct medical costs were compared accord-
ing to the initial therapy for cSSSI treatment. The mean 
total cost for combined therapy was $4,781 ± 7,361 per 
person, which was higher than monotherapy ($3,480 
± 3,307 per person). The antibiotic costs for combined 
therapy were also higher than monotherapy ($770 ± 1,117 
and $526 ± 642, respectively). Both the mean total cost 
per person and antibiotic cost were significantly higher 
in combined therapy than monotherapy (Table 3).
Table 3. Comparison of clinical characteristics and economic burden by initial therapy for community-onset complicated skin 
and skin structure infections
Characteristic Monotherapya (n = 202) Combination therapyb  (n = 247) p valuec
Charlson comorbidity index 0.719
0–2 179 (88.6) 215 (87.0)
≥ 3 23 (11.4) 32 (13.0)
Severity (SEWS) 0.316
0–3 190 (94.1) 225 (91.1)
≥ 4 12 (5.9) 22 (8.9)
Depth of infection 0.217
Subcutaneous 131 (64.9) 145 (58.7)
below fascia 71 (35.1) 102 (41.3)
Clinical burden
Hospital length of stay, day 14 (8–25) 19 (9–30) 0.057d
ICU admission 14 (6.9) 30 (12.1) 0.091
Recurrence after 3 mon 10 (5.1) 5 (2.2) 0.118
In-hospital mortality 4 (2.0) 15 (6.1) 0.035
Economic burdene
Total direct medical cost per person, $ 3,480 ± 3,307 4,781 ± 7,361 0.013
Antibiotics cost, $ 526 ± 642 770 ± 1,117 0.004
Values are presented as number (%), median (interquartile range), or mean ± SD.
SEWS, standardized early warning scoring; ICU, intensive care unit.
aMonotherapy and combination therapy were determined according to the number of antibiotics in treatment. In regardless 
of class counted in antibiotics, using only one antibiotic drug was defined as monotherapy whereas using multiple antibiotics 
was considered as combination therapy.
bUsing multiple antibiotics.
cp value by chi-square test.
dp value by Mann-Whitney test. 
ep value by t test.
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Factors related to mortality in cSSSI
In terms of mortality factors, admission via the ER (odds 
ratio [OR], 7.89; p = 0.006), CCI ≥ 3 (OR, 7.51; p < 0.001), 
SEWS ≥ 4 (OR, 18.80; p < 0.001), deep fascial space in-
fections (OR, 14.93; p < 0.001), combination therapy as 
initial therapy (OR, 3.20; p = 0.042) and the presence of 
pathogen change (OR, 4.40; p = 0.002) were significantly 
related to mortality as revealed by the univariate anal-
ysis by logistic regression. In the multivariate analysis 
adjusted by age, sex, and the statistically significant fac-
tor noted in the univariate analysis, most factors were 
not significantly associated with mortality, except for 
comorbidity index, severity and depth of infection. In 
addition, combined initial therapy was marginally sig-
nificant. These associations are presented in Table 4. 







OR (95% CI) p value OR (95% CI) p valueb
Sex
Female 4 (2.5) 155 (97.5) Ref
Male 15 (5.2) 275 (94.8) 2.11 (0.69–6.48) 0.190 2.72 (0.63–11.81) 0.181
Age, yr
 < 65 11 (3.7) 290 (96.3) Ref
 ≥ 65 8 (5.4) 140 (94.6) 1.51 (0.59–3.83) 0.389 3.38 (1.00–11.48) 0.051
Admission via ER
No 2 (1.0) 207 (99.0) Ref
Yes 17 (7.1) 223 (92.9) 7.89 (1.80–34.57) 0.006 2.53 (0.48–13.31) 0.274
Charlson comorbidity index
< 3 10 (2.5) 284 (97.5) Ref
≥ 3 9 (16.4) 46 (83.6) 7.51 (2.90–19.45) < 0.001 6.32 (2.00–19.99) 0.002
Severity (SEWS) 
< 4 9 (2.2) 406 (97.8) Ref
≥ 4 10 (29.4) 24 (70.6) 18.80 (6.98–50.60) < 0.001 7.99 (2.41–26.55) 0.001
Depth of infection
Subcutaneous 2 (0.7) 274 (99.3) Ref
Below fascia 17 (9.8) 156 (90.2) 14.93 (3.40–65.47) < 0.001 8.95 (1.78–45.06) 0.008
Pathogen 
Gram (+) only 10 (4.5) 211 (95.5) Ref
Gram (–) only 3 (5.4) 53 (94.6) 0.99 (0.27–3.61) 0.991
Both Gram (+) & gram (–) 3 (15.0) 17 (85.0) 3.58 (0.93–13.79) 0.063
Initial therapy
Monotherapy 4 (2.0) 198 (98.0) Ref
Combined therapy 15 (6.1) 232 (93.9) 3.20 (1.05–9.80) 0.042 3.66 (1.00–13.33) 0.050
Superinfection
No 11 (2.9) 369 (97.1) Ref
Yes 8 (11.6) 61 (88.4) 4.40 (1.70–11.38) 0.002 2.36 (0.73–7.68) 0.153
Values are presented as number (%).
OR, odds ratio; CI, confidence interval; ER, emergency room; SEWS, standardized early warning scoring.
aValues are number of patients and percentage in each group; p value by logistic regression.
bp = 0.942 by Hosmer and Lemeshow test.
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DISCUSSION
In the present study, we identified epidemiological 
characteristics, clinical/economic burden and the fac-
tors associated with the burdens of community-onset 
cSSSIs patients in Korea. Of the detected cSSSIs, ma-
jor abscess and cellulitis were predominant. More than 
one-third of the patients had deep fascial space infec-
tions. Approximately 40% of culture confirmed patho-
gens were S. aureus. These results are consistent with 
previous epidemiologic studies in Europe and the Unit-
ed States [10,12]. 
The clinical burden of community-onset cSSSI ob-
served in our study was notable. The median hospi-
talization period was > 2 weeks and almost 10% of the 
patients were admitted to the ICU. In addition, 3.3% of 
patients had a relapse within three months after treat-
ment, and 4.2% of patients died while admitted to the 
hospital. A similar mortality rate is reported in a previ-
ously conducted European study [10]. The factors indi-
cating more severe conditions at baseline such as higher 
CCI score (≥ 3), higher SEWS (≥ 4) and infection below 
fascia were associated with increased mortality risk. 
In addition to the baseline severity of infection, a high 
economic burden of disease was seen. The total medi-
cal costs were $4,195 per person. These costs for cSSSI 
treatment are much lower than those reported in the 
USD $48,033 [11], especially when considering the pub-
lic reimbursement system by the Korean government 
and economic gap between Korea and the United States. 
Over 50% of the total medical costs were comprised of 
costs for admission and treatment in this study. Never-
theless, total costs and mean cost of antibiotics for com-
bined therapy were relatively higher than monotherapy. 
Since higher clinical and economic burdens of CSSSI 
were proven, it is essential to investigate the potential 
factors associated with severe disease burdens. Among 
many factors, the failure of initial antibiotic therapy was 
found to be significantly related to the unfavorable clin-
ical and economic outcomes [13]. In this study, we cate-
gorized the initial therapy into two types, monotherapy 
versus combination therapy, and compared their clini-
cal and economic outcomes. As a result, patients treated 
with combination therapy showed longer hospital stays 
and higher in-hospital mortality than those on mono-
therapy. Likewise, medical costs were higher in combi-
nation therapy than monotherapy. However, direct as-
sociation or causal relationship between two therapeutic 
types and disease outcomes might be clarified in further 
studies which should be well designed prospectively. 
Several studies investigating epidemiological charac-
teristics, clinical outcomes, and treatment cost of cSSSI 
patients have been conducted in foreign countries. To 
the best of our knowledge, this is the very first study that 
observed epidemiological characteristics, clinical and 
economic burden of community-onset cSSSI patients, 
reflecting real world clinical practice in Korea. Further-
more, since this study was a nationwide study conduct-
ed in multiple centers across Korea, its outcomes are 
representative of the population and are applicable to 
the general population. It follows that the results of this 
study are expected to improve awareness of the disease 
burden of community-onset cSSSIs in Korean patients, 
and will encourage clinicians to select appropriate 
monotherapy as the initial treatment option. 
This study has several limitations, some of which 
stem from its retrospective design. This study exclud-
ed a large number of patients with cSSSIs who did not 
complete treatment in the hospital; this was important 
since this study focused on the disease burden from di-
agnosis to treatment completion. In addition, this study 
did not consider the events that occurred outside of 
the hospital, so the mortality rate should be interpret-
ed carefully. Moreover, it should be acknowledged that 
due to the nature of cost data in non-normal distribu-
tion, the data on medical cost was skewed to one side, 
which resulted in the large standardized deviation. So, 
the direct medical costs should be cautiously evaluated. 
Finally, only direct medical costs were considered, and 
thus, the actual economic burden due to cSSSIs in Kore-
an patients is higher when indirect costs are considered. 
Further study of these medical expenses could provide a 
holistic understanding of cSSSI management from the 
Korean context. 
KEY MESSAGE
1. The epidemiological characteristics of Korean 
community-onset complicated skin and skin 
structure infection (cSSSI) patients were similar 
to patients with cSSSI in other countries. Kore-
an patients with community-onset cSSSI suffer 
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